MongoDB (NASDAQ:MDB – Free Report) had its price target reduced by Oppenheimer from $400.00 to $330.00 in a research report ...

Please contact your representative at Oppenheimer & Co to request a 1-on ... of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on ...

CINCINNATI--(BUSINESS WIRE)-- Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer ... reflect those of Nasdaq, Inc. Sign up for our ...

As of March 4, 2025, the average one-year price target for Abeona Therapeutics is $16.22/share. The forecasts range from a low of $9.60 to a high of $22.05. The average price target represents an ...

Oppenheimer & Co. Inc. raised its stake in First Trust BuyWrite Income ETF (NASDAQ:FTHI – Free Report) by 17.3% during the 4th quarter, Holdings Channel reports. The fund owned 11,818 shares of the ...

Oppenheimer Asset Management Inc. acquired a new stake in shares of Texas Capital Bancshares, Inc. (NASDAQ:TCBI – Free Report ...

Oppenheimer Asset Management Inc. reduced its position in Progyny, Inc. (NASDAQ:PGNY – Free Report) by 72.3% in the 4th ...

Oppenheimer & Co. Inc. acquired a new stake in StepStone Group LP (NASDAQ:STEP – Free Report) during the 4th quarter, ...

Oppenheimer Asset Management Inc. decreased its holdings in Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL – Free Report ...

Oppenheimer Asset Management Inc. cut its holdings in Gibraltar Industries, Inc. (NASDAQ:ROCK – Free Report) by 37.5% during ...

Marvell Technology (NASDAQ:MRVL – Free Report) had its price objective cut by Citigroup from $136.00 to $122.00 in a research ...

Oppenheimer Asset Management Inc. decreased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by ...